ADA Standards of Care: Pharmacologic Treatment of Obesity in Adults

The ADA's new Obesity Association guideline reframes obesity pharmacotherapy around treating obesity-related diseases rather than weight targets alone, elevates GLP-1RA and dual GIP/GLP-1RA agents to preferred status across multiple comorbidities, and mandates indefinite continuation to prevent weight recurrence.

📅 Journal publication: Jan 13, 2026 · Last updated: Jul 16, 2026

ADA Standards of Care in Overweight and Obesity 2025The Obesity Association (American Diabetes Association)obesity/overweightGLP-1 receptor agonistsdual GIP/GLP-1 receptor agonistsphentermine-topiramatenaltrexone-bupropionorlistat Obesity / Weight Management

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Authors: American Diabetes Association Professional Practice Committee for Obesity

Citation: American Diabetes Association Professional Practice Committee for Obesity Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity. BMJ open diabetes research & care. 2026;13(Suppl 1). doi:10.1136/bmjdrc-2025-005729

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Founding member rate

$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.